Objective
In Europe over 400,000 (US >250,000, globally >1M) men are diagnosed with prostate cancer every year and well over half will have intermediate to low risk disease. The vast majority of these men would benefit from active surveillance (AS) - monitoring of disease progression before treatment. But most are treated by surgery, radiation or drugs because existing diagnostic tools do not adequately support the AS vs. treatment decision. For those men on AS the tests do easily allow long term repeated monitoring. The over-treatment of prostate cancer is a widely acknowledged and serious issue: the side effects of treatment are often worse than the disease itself and impact negatively on quality of life. We have discovered, developed and patented a blood protein signature that can discriminate between disease that remains confined to the prostate or has spread beyond it. This multiplexed protein signature, the OCProDx test, has the capacity to support at least three key patient decisions. i) for men newly diagnosed with prostate cancer: the decision between AS and treatment; ii) for men on AS: whether to treat or not, and iii) for those to be treated: which treatment may be the best option. The OCProDx test, will be licensed to a newly founded UCD Spin out company 'Atturos’. The market size is very large, the need significant and the estimated gross profit margin very attractive. We believe there is a compelling opportunity to grow Atturos to develop OCProDx within a commercial setting and deliver it to market. In so doing, Atturos will grow rapidly to create high value EU employment opportunities that will be global in reach. Well-resourced laboratory based studies are currently underway to consolidate the technical performance of OCProDx and validate its clinical performance. In this proposal we seek to engage with key external consultants to develop and produce a detailed business plan for Atturos to commercialise and monetise OCProDx.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology prostate cancer
- medical and health sciences clinical medicine surgery
- medical and health sciences clinical medicine urology
- natural sciences biological sciences biochemistry biomolecules proteins
- natural sciences chemical sciences analytical chemistry mass spectrometry
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3.1.3. - Treating and managing disease
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
A96 E8H2 DUBLIN
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.